Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-०.३२%
१,०८८.०४
-३.४७
-०.३२%
—१,०९१.५११,०९०.४०१,०९०.४०१,०८१.९७——
SIXC
Communications
SIXC
Communications
SIXC
-०.०८%
६०९.६३
-०.४८
-०.०८%
—६१०.११६१०.११६१०.११६०६.१७——
SIXE
Energy
SIXE
Energy
SIXE
+०.३०%
१,२४१.७१
+३.७३
+०.३०%
—१,२३७.९८१,२३७.८३१,२४५.३४१,२२५.०३——
SIXI
Industrials
SIXI
Industrials
SIXI
+०.१०%
१,७४६.६५
+१.८३
+०.१०%
—१,७४४.७११,७४०.९५१,७४७.२९१,७३५.६४——
SIXM
Financials
SIXM
Financials
SIXM
+०.१५%
६४१.१५
+०.९७
+०.१५%
—६४०.१८६३९.९२६४३.१९६३६.७०——
SIXR
Staples
SIXR
Staples
SIXR
+०.००%
८४९.६०
+०.०२०
+०.००%
—८४९.५८८४५.२७८५१.६८८४१.२८——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+०.१९%
२१७.९०
+०.४२
+०.१९%
—२१७.४८२१७.४८२१८.१६२१६.३९——
SIXT
Technology
SIXT
Technology
SIXT
+०.६७%
३,२८२.६२
+२१.९३
+०.६७%
—३,२६०.६९३,२७३.३६३,२८७.८१३,२६९.०७——
SIXU
Utilities
SIXU
Utilities
SIXU
+०.३८%
९४६.२२
+३.६०
+०.३८%
—९४२.४५९३९.३९९४८.८०९३४.०४——
SIXV
Health care
SIXV
Health care
SIXV
-०.११%
१,४६५.२०
-१.६०
-०.११%
—१,४६६.८०१,४६४.७०१,४६७.१९१,४५८.६८——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+०.५३%
२,४१०.३२
+१२.८२
+०.५३%
—२,३९७.५०२,३९५.०३२,४११.२२२,३९१.९८——
HALO:NASDAQ
Halozyme Therapeutics, Inc.
US$ ६४.४३
+०.७३%
(+०.४७) 1D
मे ४, १०:५८:४९ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HALO...
Open
US$ ६३.५०
High
US$ ६४.६८
Low
US$ ६३.११
Mkt. cap
७.६६ अरब
Volume
१.२९ लाख
P/E ratio
२५.१९
52-wk high
US$ ८२.२२
52-wk low
US$ ४७.५०
EPS
US$ २.५६
Beta
०.८९
Shares outstanding
११.८५ करोड
No. of employees
४२३
News stories
From sources across the web
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees४२३
Founded१९९८
Headquartersसान डिएगो, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Websitehalozyme.com
Next call ७ दिनमा
मे ११, सोम, १६:३०
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (१.५२ est.)USD
Revenue / Estimate
-/ (३५.९१ करोड est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
२०२५ मार्च
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
Revenue
२६.४९ करोड
३२.५७ करोड
३५.४३ करोड
४५.१८ करोड
Cost of goods sold
६.३२ करोड
४.६४ करोड
७.२५ करोड
११.०७ करोड
Cost of revenue
६.३२ करोड
४.६४ करोड
७.२५ करोड
११.०७ करोड
Research and development expenses
-
१.७५ करोड
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
४.२४ करोड
४.१६ करोड
४.६१ करोड
६.३३ करोड
Operating expense
६.०१ करोड
७.६९ करोड
६.३८ करोड
८.६७ करोड
Total operating expenses
१२.३३ करोड
१२.३३ करोड
१३.६३ करोड
१९.७४ करोड
Operating income
१४.१५ करोड
२०.२४ करोड
२१.७९ करोड
२५.४४ करोड
Other non operating income
-
६८.९१ लाख
-
-
EBT including unusual items
१४.३८ करोड
२०.४९ करोड
२१.९० करोड
-१०.०८ करोड
EBT excluding unusual items
१४.२१ करोड
२०.४९ करोड
२१.९० करोड
२५.१६ करोड
Income tax expense
२.५७ करोड
३.९८ करोड
४.३७ करोड
४.०७ करोड
Effective tax rate
१७.८९%
१९.४१%
१९.९७%
-४०.४०%
Other operating expenses
-
-
-
-
Net income
११.८१ करोड
१६.५२ करोड
१७.५२ करोड
-१४.१६ करोड
Net profit margin
४४.५९%
५०.७१%
४९.४६%
-३१.३४%
Earnings per share
१.११
१.५४
१.७२
-०.२४
Interest and investment income
५१.०९ लाख
-
५३.३३ लाख
२०.९० लाख
Interest expense
-४५.२५ लाख
-४३.९४ लाख
-४२.९६ लाख
-४९.११ लाख
Net interest expenses
५.८४ लाख
-४३.९४ लाख
१०.३७ लाख
-२८.२१ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
१६.०५ करोड
२२.१४ करोड
२३.६८ करोड
२७.९१ करोड
Gain or loss from assets sale
-
-
-
२६.२१ लाख
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer